18 recruiting, 14 not yet recruiting, 5 completed, 5 unknown. 35 Phase 2, 8 Phase 3, 4 Not applicable, 1 Phase 1.
Follow Short-course radiotherapy: new trials by email Literature Review of Short-course radiotherapy trials Research Report on Short-course radiotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial Short-course radiotherapy, CAPOX (oxaliplatin/capecitabine), Sintilimab - Local Advanced Rectal Cancer, PD-1 Inhibitor | Phase 3 | Not yet recruiting | Guangdong Provincial People's Hospital | 148 | 2027-01-01 | 2026-07-07 |
| A Prospective, Biomarker-Stratified Phase 2 Study: β-Hydroxybutyrate as a Predictive Biomarker for Short-Course Radiotherapy Followed by Chemotherapy Plus PD-1 Inhibitor Versus Chemotherapy Alone in Locally Advanced Rectal Cancer Short-course radiotherapy, Capecitabine, Oxaliplatin - Rectal Cancer, Radiotherapy | Phase 2 | Not yet recruiting | Tao Zhang | 144 | 2026-11-01 | 2026-10-06 |
| Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS short-course radiotherapy, Serplulimab, CapOx(Capecitabine+ Oxaliplatin) - Locally Advanced Colon Cancer, pMMR | Phase 3 | Not yet recruiting | Fudan University | 480 | 2026-10-15 | 2026-10-16 |
| NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 2 | Not yet recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 100 | 2026-09-01 | 2026-08-14 |
| Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal Cancer Serine/Glycine-Restricted Diet, CAPOX Chemotherapy, PD-1 Inhibitor - Locally Advanced Rectal Cancer (LARC) | Phase 1 / Phase 2 | Not yet recruiting | Xuelei Ma MD | 140 | 2026-08-31 | 2026-09-09 |
| Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer Short-Course Radiotherapy, Consolidation treatment (With ICIs), Consolidation treatment (Without ICIs) - Local Advanced Rectal Cancer, Radiotherapy | Phase 3 | Recruiting | Shandong Cancer Hospital and Institute | 180 | 2026-08-15 | 2026-08-18 |
| To Explore a Single-arm Phase II Study on Intestinal Microbiota Transplantation Combined With Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Rectal Cancer Under MSS/pMMR Sintilimab, CAPOX (oxaliplatin/capecitabine), Short-course radiotherapy - Locally Advanced Rectal Cancer (LARC) | Not applicable | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 46 | 2026-07-31 | 2026-07-30 |
| Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC Short-course radiotherapy, Long-course radiotherapy, Immunotherapy - Locally Advanced Rectal Adenocarcinoma, Neoadjuvant Chemoradiation | Phase 2 / Phase 3 | Not yet recruiting | Beijing Friendship Hospital | 342 | 2026-07-15 | 2026-06-17 |
| Neoadjuvant PD-1 Inhibitor Plus SOX Chemotherapy With or Without Short-Course Radiotherapy for Locally Advanced Upper Gastric or GEJ Adenocarcinoma Short-course Radiotherapy, Neoadjuvant Serplulimab and SOX Chemotherapy - Locally Advanced Proximal Gastric or Gastroesophageal Junction Adenocarcinoma | Not applicable | Not yet recruiting | Tongji Hospital | 146 | 2026-06-30 | 2026-06-29 |
| Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer Short-Course Radiotherapy, Liposomal Irinotecan (nal-IRI), Capecitabine - Rectal Cancer Patients | Phase 2 | Not yet recruiting | Guangdong Provincial People's Hospital | 44 | 2026-05-20 | 2026-04-13 |
| SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 3 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 204 | 2026-05-20 | 2026-07-01 |
| A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer Short-course radiotherapy, Long-course radiotherapy, Capecitabine - Rectal Cancer, Total Neoadjuvant Therapy | Phase 3 | Recruiting | Tao Zhang | 444 | 2026-05-15 | 2026-05-13 |
| A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer Serplulimab, Oncolytic Virus H101, XELOX Chemotherapy - Rectal Neoplasms, Rectal Adenocarcinoma | Phase 2 | Not yet recruiting | Chongqing University Cancer Hospital | 20 | 2026-05-01 | 2026-04-22 |
| Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer SHR-1701, SHR-8068, Short-course radiotherapy - Locally Advanced Colorectal Cancer | Phase 2 | Not yet recruiting | Fudan University | 134 | 2026-04-01 | 2026-03-31 |
| Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) short-course radiotherapy, Zanidatamab, Tisleizumab(BGB-A317) - Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | Tao Zhang | 70 | 2026-01-15 | 2025-11-24 |
| A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer Short-course radiotherapy, Capecitabine, Oxaliplatin - Rectal Cancer, Radiotherapy | Phase 2 | Recruiting | Tao Zhang | 25 | 2026-01-01 | 2026-04-23 |
| A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer Short-course radiotherapy, CAPOX chemotherapy, Targeted therapy with bevacizumab - Locally Advanced Rectal Cancer (LARC) | Phase 2 | Recruiting | First Affiliated Hospital of Wenzhou Medical University | 30 | 2025-12-01 | 2026-01-16 |
| SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC SCRT, Liposomal Irinotecan, Oxaliplatin - Rectal Cancer, Adenocarcinoma | Not applicable | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 49 | 2025-11-30 | 2026-03-16 |
| SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer Short-Course Radiotherapy, Fruquintinib, Tislelizumab - Rectal Neoplasms, Rectal Cancer, Adenocarcinoma | Phase 2 | Recruiting | Ruijin Hospital | 50 | 2025-09-11 | 2026-10-22 |
| Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC) Long-course radiotherapy, Oxaliplatin, Capecitabine - Locally Advanced Rectal Cancer, Neoadjuvant Therapy | Phase 2 | Recruiting | Fudan University | 138 | 2025-08-28 | 2025-09-02 |
Showing 20 of 46. Sign in to see all of them.
Rectal Neoplasms (24) · Colorectal Neoplasms (2) · Colonic Neoplasms (1)
Fudan University (7) · Tao Zhang (4) · Sixth Affiliated Hospital, Sun Yat-sen University (3) · Guangdong Provincial People's Hospital (2) · Ruijin Hospital (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) · Alexander Valdman (1) · Beijing Friendship Hospital (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Chinese Academy of Medical Sciences (1) · Chongqing University Cancer Hospital (1) · First Affiliated Hospital of Wenzhou Medical University (1) · First Affiliated Hospital of Zhejiang University (1) · Fujian Cancer Hospital (1) · Gruppo Oncologico del Nord-Ovest (1)
China (38) · Italy (1) · South Korea (1) · Sweden (1) · Taiwan (1)
Zhen Zhang, M.D, PH.D (3) · Zhen Zhang, MD (2) · Zhenyu Lin (2) · Guohui Wan, PhD. (1) · Hongli Liu, Professor (1) · Jinbo Yue, Doctor (1) · Juan Huang, PhD. (1) · Jun Huang, PhD (1) · Jun Huang, PhD. (1) · Pei Xue (1) · Peirong Ding, MD, Ph D (1) · Ren Zhao, MD, PHD (1) · Roberto Moretto, MD (1) · Sanjun Cai, MD (1)
PMID 35291966, PMID 37802608, PMID 37923987, PMID 38200410, PMID 38950321, PMID 39020518, PMID 40204311, PMID 40845854, PMID 42495710